Actemra (Tocilizumab 200mg), imported by JW Pharmaceutical and used to treat rheumatoid arthritis, is also expected to be paid for CRS management. The MOHW announced on the 18th some amendments to the "Details on the Application Criteria and Methods of Nursing Benefits" containing such contents. Actemra is a drug approved for adult rheumatoid arthritis treatment, systemic childhood idiopathic arthritis, and multi-articular childhood idiopathic arthritis.

CRS develops symptoms due to excessive release of cytokines from immune cells in the process of killing cancer cells. The MOHW plans to recognize benefits when administering Actemra to CRS management.

The government plans to conduct an in